Lurbinectedin monotherapy (SCLC, relapsed/refractory, ≥2L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-LURBINECTEDIN`

ID	`REG-LURBINECTEDIN-SCLC-RR`
Type	Regimen
Status	reviewed 2026-04-29 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-SCLC-2021` `SRC-NCCN-SCLC-2025`

Notes

Single-agent lurbinectedin for relapsed/refractory SCLC after platinum-based 1L. Phase II basket trial (Trigo et al. Lancet Oncol 2020) — ORR 35.2% overall; platinum-sensitive (CTFI ≥90 days) ORR 45%, mDOR 6.2 mo, mOS 11.9 mo; platinum-resistant (CTFI <90 days) ORR 22%, mDOR 4.7 mo, mOS 5.0 mo. ATLANTIS Phase III (lurbinectedin + doxorubicin vs CAV/topotecan, 2L SCLC) did NOT meet OS primary endpoint (mOS 8.6 vs 7.6 mo, HR 0.97) — combination arm not superior; monotherapy use rests on FDA accelerated-approval basket trial data + NCCN Category 2A listing. STUB — pending ATLANTIS / Trigo trial Source ingestion (SRC-ATLANTIS-PAZ-ARES-2023, SRC-TRIGO-2020) and Co-Lead sign-off.

Used By

Indication

IND-SCLC-RR-LURBINECTEDIN - IND-SCLC-RR-LURBINECTEDIN

Regimen

REG-TARLATAMAB - Tarlatamab — 2L+ extensive-stage SCLC (DeLLphi-301; DLL3 × CD3 BiTE)